Perjeta

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by intravenous infusion
gptkbp:approves gptkb:2012
gptkb:FDA
gptkbp:atccode L01 XC13
gptkbp:can_be_combined_with gptkb:trastuzumab
chemotherapy
gptkbp:chemical_formula C6460 H10080 N1716 O2016 S44
gptkbp:clinical_trial Phase III
gptkbp:clinical_use neoadjuvant therapy
first-line therapy
second-line therapy
HER2-positive gastric cancer
gptkbp:contraindication pregnancy
severe heart failure
lactation
hypersensitivity to pertuzumab
concurrent use of anthracyclines
gptkbp:developed_by gptkb:Genentech
gptkbp:dosage_form solution for infusion
https://www.w3.org/2000/01/rdf-schema#label Perjeta
gptkbp:indication metastatic breast cancer
adjuvant treatment
gptkbp:ingredients gptkb:pertuzumab
gptkbp:invention patented
gptkbp:manufacturer gptkb:Roche
gptkbp:marketed_as gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkb:brand
gptkbp:mechanism_of_action HER2 receptor antagonist
gptkbp:name Essential Medicines
gptkbp:research_areas gptkb:immunotherapy
oncology
biologics
targeted therapy
gptkbp:route_of_administration IV
gptkbp:shelf_life 24 months
gptkbp:side_effect gptkb:anemia
fatigue
nausea
diarrhea
heart problems
thrombocytopenia
infusion-related reactions
neutropenia
hypersensitivity reactions
gptkbp:storage refrigerated
gptkbp:trade gptkb:Perjeta
gptkbp:used_for treatment of breast cancer
treatment of HER2-positive breast cancer
gptkbp:bfsParent gptkb:Genentech
gptkbp:bfsLayer 4